Cargando…
Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers
The high occurrence of bladder cancer and its tendency to recur in combination with a lifelong surveillance make the treatment of superficial bladder cancer one of the most expensive and time-consuming. Moreover, carcinoma in situ often leads to muscle invasion with an unfavorable prognosis. Current...
Autores principales: | Matuszczak, Milena, Salagierski, Maciej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247579/ https://www.ncbi.nlm.nih.gov/pubmed/32397531 http://dx.doi.org/10.3390/ijms21093360 |
Ejemplares similares
-
Evaluation of CYFRA 21.1 as a Dedifferentiation Marker of Advanced Thyroid Cancer
por: Malapure, Sumeet Suresh, et al.
Publicado: (2020) -
Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer
por: Giovanella, L., et al.
Publicado: (2017) -
Serum CYFRA 21.1 Level Predicts Disease Course in Thyroid Cancer with Distant Metastasis
por: Jeong, Chaiho, et al.
Publicado: (2021) -
A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers
por: Matuszczak, Milena, et al.
Publicado: (2022) -
Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.
por: van der Gaast, A., et al.
Publicado: (1994)